{"title":"Knockdown of USP22 alleviates LPS-induced microglial inflammation and mouse depressive-like behaviors via KAT2A","authors":"Yan Lu, Yuhan Zheng, Xiaoru Sun, Yujie Song, Yilu Zhou, Fuyi Shen, Rongrong Huang, Zhendong Xu","doi":"10.1038/s41386-025-02207-y","DOIUrl":null,"url":null,"abstract":"Depression is a chronic mental illness that has emerged as the second most prevalent disease globally, characterized by symptoms such as low mood, reduced interest, and cognitive impairment. The onset of depression has been associated with microglial inflammation, but the molecular mechanisms behind this are not well understood. Here, we investigated the mechanisms involved in the roles of microglial inflammation in promoting depression by establishing a mouse model of inflammation-related depression via lipopolysaccharide (LPS) administration. We found that LPS treatment led to microglial activation and increased the deubiquitinating enzyme, USP22, expression in the mouse hippocampus. Further, knockdown of USP22 in microglia inhibited depressive-like behaviors and intracerebral inflammation in the mouse model. Moreover, subsequent mechanistic analyses revealed that KAT2A, which serves as a ubiquitination substrate, is modulated by USP22, thereby influencing mitochondrial damage and oxidative stress in microglia. Our findings indicate that USP22 facilitates oxidative stress and inflammatory responses in microglia through the deubiquitination of KAT2A, providing a promising target for the development of therapeutic strategy for the depression treatment.","PeriodicalId":19143,"journal":{"name":"Neuropsychopharmacology","volume":"50 12","pages":"1904-1912"},"PeriodicalIF":6.6000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41386-025-02207-y.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41386-025-02207-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Depression is a chronic mental illness that has emerged as the second most prevalent disease globally, characterized by symptoms such as low mood, reduced interest, and cognitive impairment. The onset of depression has been associated with microglial inflammation, but the molecular mechanisms behind this are not well understood. Here, we investigated the mechanisms involved in the roles of microglial inflammation in promoting depression by establishing a mouse model of inflammation-related depression via lipopolysaccharide (LPS) administration. We found that LPS treatment led to microglial activation and increased the deubiquitinating enzyme, USP22, expression in the mouse hippocampus. Further, knockdown of USP22 in microglia inhibited depressive-like behaviors and intracerebral inflammation in the mouse model. Moreover, subsequent mechanistic analyses revealed that KAT2A, which serves as a ubiquitination substrate, is modulated by USP22, thereby influencing mitochondrial damage and oxidative stress in microglia. Our findings indicate that USP22 facilitates oxidative stress and inflammatory responses in microglia through the deubiquitination of KAT2A, providing a promising target for the development of therapeutic strategy for the depression treatment.
期刊介绍:
Neuropsychopharmacology is a reputable international scientific journal that serves as the official publication of the American College of Neuropsychopharmacology (ACNP). The journal's primary focus is on research that enhances our knowledge of the brain and behavior, with a particular emphasis on the molecular, cellular, physiological, and psychological aspects of substances that affect the central nervous system (CNS). It also aims to identify new molecular targets for the development of future drugs.
The journal prioritizes original research reports, but it also welcomes mini-reviews and perspectives, which are often solicited by the editorial office. These types of articles provide valuable insights and syntheses of current research trends and future directions in the field of neuroscience and pharmacology.